|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 31/7076 | (2006.01) |
| A61K 38/21 | (2006.01) | ||
| A61K 9/20 | (2006.01) | ||
| A61P 25/00 | (2006.01) |
| (11) | Number of the document | 2805723 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14001970.4 |
| Date of filing the European patent application | 2005-12-20 | |
| (97) | Date of publication of the European application | 2014-11-26 |
| (45) | Date of publication and mention of the grant of the patent | 2018-01-17 |
| (46) | Date of publication of the claims translation | 2018-02-12 |
| (30) | Number | Date | Country code |
| 638669 P | 2004-12-22 | US | |
| 04106909 | 2004-12-22 | EP |
| (72) |
De Luca, Giampiero, CH
Ythier, Arnaud, CH
Munafo, Alain, CH
Lopez-Bresnahan, Maria, US
|
| (73) |
Merck Serono SA,
Centre Industriel, 1267 Coinsins, Vaud,
CH
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kladribino režimas, skirtas išsėtinei sklerozei gydyti |
| Cladribine regimen for treating multiple sclerosis |
| Payment date | Validity (years) | Amount | |
| 2022-12-15 | 18 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2023-09-12 |